The European Medicines Agency (EMA) published on Friday 24 February the main decisions of its Committee for Medicinal Products for Human Use (CHMP) and two decisions concerning medical products related to Covid-19.
On the one hand, CHMP recommends authorising the use of the inactivated and adjuvanted vaccine developed against Covid-19 byValneva (see EUROPE B12980A20) for use as a booster dose in adults aged 18-50 years.
In addition, the CHMP reviewed all data received in the context of...